Steven Cohen Biotechnology

Point72 Asset Management, L.P.

$40.1 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade
ASND Ascendis Pharma A/S	$10.2B	$88.7 Million 0.22% of portfolio	569,146	Q1 2025 Added 13.0%
ALNY Alnylam Pharmaceuticals, Inc.	$52.7B	$81.2 Million 0.2% of portfolio	300,635	Q1 2025 New
ACAD Acadia Pharmaceuticals Inc	$3.85B	$77.2 Million 0.19% of portfolio	4,647,816	Q1 2025 Added 108.35%
PTCT Ptc Therapeutics, Inc.	$3.67B	$70 Million 0.17% of portfolio	1,373,573	Q1 2025 Reduced 4.84%
CYTK Cytokinetics Inc	$3.31B	$69.2 Million 0.17% of portfolio	1,722,984	Q1 2025 Added 914.04%
BGNE Bei Gene, Ltd.	$23.5B	$50.7 Million 0.13% of portfolio	223,443	Q1 2025 Added 787.88%
SNDX Syndax Pharmaceuticals Inc	$729M	$49.3 Million 0.12% of portfolio	4,008,700	Q1 2025 Added 109.25%
CLDX Celldex Therapeutics, Inc.	$1B	$47.6 Million 0.12% of portfolio	2,621,175	Q1 2025 Added 4.18%
RARE Ultragenyx Pharmaceutical Inc.	$1.96B	$35.3 Million 0.09% of portfolio	976,052	Q1 2025 Reduced 17.48%
CNTA Centessa Pharmaceuticals PLC	$1.62B	$32.9 Million 0.08% of portfolio	2,286,433	Q1 2025 Reduced 33.27%
COGT Cogent Biosciences, Inc.	$721M	$31.7 Million 0.08% of portfolio	5,295,545	Q1 2025 Reduced 0.97%
BCYC Bicycle Therapeutics PLC	$224M	$31.3 Million 0.08% of portfolio	3,692,069	Q1 2025 Reduced 18.94%
IMNM Immunome Inc.	$133M	$29.3 Million 0.07% of portfolio	4,360,675	Q1 2025 Added 533.09%
TECH Bio Techne Corp	$1.96B	$29.2 Million 0.07% of portfolio	497,655	Q1 2025 New
RLAY Relay Therapeutics, Inc.	$424M	$28.4 Million 0.07% of portfolio	10,827,067	Q1 2025 Added 579.77%
BMRN Biomarin Pharmaceutical Inc	$11.3B	$28 Million 0.07% of portfolio	395,750	Q1 2025 Added 48.53%
CRNX Crinetics Pharmaceuticals, Inc.	$1.53B	$26.1 Million 0.07% of portfolio	778,398	Q1 2025 Reduced 72.09%
FOLD Amicus Therapeutics, Inc.	$1.94B	$24.4 Million 0.06% of portfolio	2,985,108	Q1 2025 New
RCUS Arcus Biosciences, Inc.	$685M	$22.5 Million 0.06% of portfolio	2,867,097	Q1 2025 Added 43.62%
IMVT Immunovant, Inc.	$3.55B	$22.1 Million 0.06% of portfolio	801,927	Q1 2025 New
MDGL Madrigal Pharmaceuticals, Inc.	$5.78B	$21.8 Million 0.05% of portfolio	65,860	Q1 2025 New
JAZZ Jazz Pharmaceuticals PLC	$6.64B	$21.6 Million 0.05% of portfolio	173,870	Q1 2025 Added 106.62%
INCY Incyte Corp	$17.3B	$20.7 Million 0.05% of portfolio	342,014	Q1 2025 Reduced 73.25%
AKRO Akero Therapeutics, Inc.	$2.45B	$20.6 Million 0.05% of portfolio	508,340	Q1 2025 Reduced 43.5%
IMCR Immunocore Holdings PLC	$1.41B	$18.6 Million 0.05% of portfolio	628,292	Q1 2025 Added 55.79%
GMAB Genmab A/S	$14.2B	$18.1 Million 0.05% of portfolio	923,867	Q1 2025 Added 948.11%
ADMA Adma Biologics, Inc.	$3.64B	$16.8 Million 0.04% of portfolio	847,558	Q1 2025 Added 299.18%
DYN Dyne Therapeutics, Inc.	$600M	$16 Million 0.04% of portfolio	1,528,534	Q1 2025 Added 65.3%
TRVI Trevi Therapeutics, Inc.	$433M	$14.9 Million 0.04% of portfolio	2,368,005	Q1 2025 Reduced 42.94%
AXSM Axsome Therapeutics, Inc.	$4.43B	$14.7 Million 0.04% of portfolio	126,193	Q1 2025 Reduced 31.84%
OCUL Ocular Therapeutix, Inc	$962M	$14.2 Million 0.04% of portfolio	1,942,362	Q1 2025 Reduced 33.84%
ARQT Arcutis Biotherapeutics, Inc.	$924M	$13 Million 0.03% of portfolio	830,478	Q1 2025 Reduced 52.64%
GERN Geron Corp	$525M	$11.3 Million 0.03% of portfolio	7,126,818	Q1 2025 Added 378.67%
XNCR Xencor Inc	$447M	$10.9 Million 0.03% of portfolio	1,023,673	Q1 2025 Reduced 52.98%
HRTX Heron Therapeutics, Inc.	$215M	$10.5 Million 0.03% of portfolio	4,775,877	Q1 2025 Added 55.27%
MIRM Mirum Pharmaceuticals, Inc.	$1.96B	$10.5 Million 0.03% of portfolio	232,098	Q1 2025 New
JANX Janux Therapeutics, Inc.	$1.01B	$10.2 Million 0.03% of portfolio	376,662	Q1 2025 Reduced 39.38%
PCVX Vaxcyte, Inc.	$1.96B	$9.26 Million 0.02% of portfolio	245,317	Q1 2025 Reduced 2.29%
CRVS Corvus Pharmaceuticals, Inc.	$201M	$8.86 Million 0.02% of portfolio	2,787,631	Q1 2025 Reduced 8.0%
IONS Ionis Pharmaceuticals Inc	$5.78B	$8.66 Million 0.02% of portfolio	287,204	Q1 2025 New
XENE Xenon Pharmaceuticals Inc.	$2.13B	$7.04 Million 0.02% of portfolio	209,759	Q1 2025 New
DSGN Design Therapeutics, Inc.	$243M	$7.02 Million 0.02% of portfolio	1,817,858	Q1 2025 Reduced 2.09%
BBIO Bridge Bio Pharma, Inc.	$6.64B	$6.87 Million 0.02% of portfolio	198,780	Q1 2025 New
VERV Verve Therapeutics, Inc.	$667M	$6.37 Million 0.02% of portfolio	1,393,398	Q1 2025 Reduced 0.05%
TSHA Taysha Gene Therapies, Inc.	$132M	$6.35 Million 0.02% of portfolio	4,569,678	Q1 2025 New
ROIV Roivant Sciences Ltd.	$8.21B	$6.2 Million 0.02% of portfolio	614,315	Q1 2025 New
VRNA Verona Pharma PLC	$6.42B	$5.99 Million 0.01% of portfolio	94,322	Q1 2025 Reduced 86.73%
OLMA Olema Pharmaceuticals, Inc.	$217M	$5.42 Million 0.01% of portfolio	1,441,690	Q1 2025 Reduced 60.73%
LIFE A Tyr Pharma Inc	$53.2M	$5.29 Million 0.01% of portfolio	2,844,099	Q1 2025 Reduced 41.76%
VTYX Ventyx Biosciences, Inc.	$143M	$4.87 Million 0.01% of portfolio	4,234,804	Q1 2025 Added 137.64%

Shares Options

Steven Cohen

Steven Cohen is the founder and CEO of Point72 Asset Management, a successful investment firm that uses technology and data-driven approaches to investing. Cohen is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.

Track Steven Cohen's portfolio

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account